DepoMed News

DepoMed , a specialty pharmaceutical company, announced positive phase 3 trial results for the treatment of Post Herpetic Neuralgia with DM1796.

Depomed, Inc. announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at Merriman Curhan Ford's 6th annual Investor Summit in New York, NY on November 10, 2009 at 1:00 pm EST.

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical Trials and upcoming FDA approvals & decisions.

Depomed announced earlier this week that its investigational non-hormonal therapeutic option for the treatment of menopausal hot flashes, Serada , failed to meet its primary efficacy endpoints in its two pivotal BREEZE clinical studies .

Depomed released disappointing Monday results for a phase-3 clinical trial of Serada, a treatment for hot flashes caused by menopause.

Drug stocks inched up in early action Monday as shares of DepoMed Inc. sank after it released mixed Phase III clinical data for its menopausal hotflash treatment Serada.

Depomed Inc. announced that its drug Serada, which is used to treat hot flashes brought on by menopause and is in the Phase 3 of clinical trials, showed disappointing results.

Shares of the following companies were having unusual moves in U.S. trading this morning.

Trading was a little thin due to the Columbus Day holiday Monday, and a breakdown in technical support levels caused some midsession panic, but the S&P 500 successfully logged its sixth straight gain- the best streak this year for the stock market.

Depomed Inc. opened Monday on a loss of nearly 50%, as traders panned the company's clinical trial results for Serada.

Drug stocks inched up in early action Monday as shares of DepoMed Inc. sank after it released mixed Phase III clinical data for its menopausal hot-flash treatment Serada.

The markets reversed course erasing much of last weeka s losses following a bullish report on large banks by Goldman Sachs.

Oct 5, 2009 - Depomed, Inc. today announced top-line results from a Phase 3 clinical trial demonstrating DM-1796 achieved a statistically significant reduction in pain associated with postherpetic neuralgia versus placebo using the baseline observation carried forward method required by FDA.

Drug stocks gained Monday while shares of Seattle Genetics dived after the biotech group said it was halting a Phase II clinical study for its drug candidate dacetuzumab due to disappointing results.

Option speculators have swarmed DepoMed, Inc. today, after the firm's late-stage study of its post-herpetic neuralgia treatment showed a significant reduction in pain.

Stock futures were pointing to a higher opening looking to break its four-day losing streak.

Depomed Inc. on Monday reported a successful late stage clinical trial of a drug intended to treat pain following the viral infection shingles, and its shares soared on the news.

Catalyst Pharmaceutical Partners Inc. says it will continue developing an anti-addiction drug that has failed in two clinical trials, as it believes the treatment is safe and effective.

Shares of the following companies are having unusual moves in U.S. trading this morning.

Depomed Inc. on Monday reported a successful late stage clinical trial of a drug intended to treat pain following the viral infection shingles, and its shares soared on the news.